ArticleBritish journal of cancer1997
MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Article in British journal of cancer, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature.Journal of neuro-oncology · 2010Pooled it
- Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy.AJNR. American journal of neuroradiology · 2000Trial
- Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.Brain pathology (Zurich, Switzerland) · 1998Trial
- Targeting HLA-F suppresses the proliferation of glioma cells via a reduction in hexokinase 2-dependent glycolysis.International journal of biological sciences · 2021Article
- Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway.International journal of molecular sciences · 2019Review
- p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study.Oncology letters · 2015Article
- Immunohistochemical Expression of Ki-67, PCNA and CD34 in Astrocytomas: A Clinicopathological Study.Oman medical journal · 2012Article
- MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- MDM2 regulates estrogen receptor α and estrogen responsiveness in breast cancer cells.Journal of molecular endocrinology · 2011Article
- The pathobiology of glioma tumors.Annual review of pathology · 2010Review
- Article
- Apoptosis and proliferation: correlation with p53 in astrocytic tumours.Journal of neuro-oncology · 2005Article
- Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage.British journal of cancer · 2004Article
- Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.The Journal of molecular diagnostics : JMD · 2004Article
- Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.Journal of neuro-oncology · 2004Article
- Proliferation and aneusomy predict survival of young patients with astrocytoma grade II.British journal of cancer · 2003Article
- Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.Journal of neuro-oncology · 2003Article
- The expression of p73, p21 and MDM2 proteins in gliomas.Journal of neuro-oncology · 2002Article
- Immunohistochemical markers for prognosis of cerebral glioblastomas.Journal of neuro-oncology · 2002Article
- Immunohistochemical markers for prognosis of anaplastic astrocytomas.Journal of neuro-oncology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
p53 and the murine double minute 2 (MDM2) oncoprotein expression was evaluated in paraffin-embedded tissue from 61 patients with central nervous system gliomas (53 astrocytomas and eight oligodendrogliomas) and related to proliferation-associated markers [i.e. proliferating cell nuclear antigen (PCNA), Ki-67 and nuclear organizer regions (NORs)] and epidermal growth factor receptor (EGFR). We used the monoclonal antibodies PC-10, MIB-1, DO-1, 1B1O and EGFR 113 and the colloid silver nitrate (AgNOR) technique. MDM2 and p53 were co-expressed in 28% of cases. A p53-positive/MDM2-negative phenotype was observed in 15% and a p53-negative/MDM2-positive phenotype in 20% of cases. There was a positive correlation of p53 and MDM2 expression with grade and proliferation indices. Univariate analysis in the group of diffuse astrocytomas showed that older age, high histological grade, high PCNA labelling index (LI) and high AgNOR score were associated with reduced overall survival (P < 0.05). p53 LI, Ki-67 LI, AgNOR score, tumour location and grade influenced disease-free survival (P < 0.05), whereas the only parameters affecting post-relapse survival were histological grade and Ki-67 LI (P < 0.1). Multivariate analysis revealed that age, radiotherapy, PCNA LI and p53 LI were the independent predictors of overall survival. p53 LI, Ki-67 LI, MDM2 LI, EGFR LI, grade and type of therapy were independent predictors of disease-free survival, and grade was the only independent predictor of post-relapse survival. Our results indicate that p53 LI and MDM2 LI, EGFR expression as well as proliferation markers (PCNA and Ki-67) are useful indicators of overall and disease-free survival in diffuse astrocytoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.